2012.12.11 05:43 Encouraging Progress since 2012
2023.03.25 01:16 XhetherC Silly coder man gets silly results
2023.03.24 19:42 i_know_nothing123 Astrology observations I made pt 35
2023.03.24 16:52 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to StockMarket [link] [comments] Great Partnership News with High Times Out Yesterday! Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products ‘Mindful by Lucy’ https://preview.redd.it/gt8lt6k2lppa1.jpg?width=230&format=pjpg&auto=webp&s=ccb2e562b5774e49657e46889063d2b83c65aca1 New Line of Psychoactive Products VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world. The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’. Lucy Scientific will produce Mindful with High Times, through a strategic partnership with Hightimes Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts. With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025. Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events. Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.” FULL ARTICLE Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance)Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/bydiblj3lppa1.png?width=700&format=png&auto=webp&s=cba04c7023a85a4249e0a0bd96434d6804a40f56 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.24 16:26 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to MoonBets [link] [comments] Great Partnership News with High Times Out Yesterday! Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products ‘Mindful by Lucy’ https://preview.redd.it/6s68ig7egppa1.jpg?width=230&format=pjpg&auto=webp&s=945c9fa8a34b1433d51cc1af8f54c70d865deb57 New Line of Psychoactive Products VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world. The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’. Lucy Scientific will produce Mindful with High Times, through a strategic partnership with Hightimes Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts. With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025. Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events. Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.” FULL ARTICLE Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance)Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. RSI of 35.34 https://preview.redd.it/sdlepuufgppa1.png?width=700&format=png&auto=webp&s=c390de69383fb860e2cb25eca917cd0fe3f93f83 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.24 05:58 Plenty_Ad3169 I have a crush on a guy that I shouldn’t and it’s tearing me apart.
2023.03.24 05:29 deeplyinsecure2001 I (17m) don’t want to be alone anymore
2023.03.24 02:02 Accomplished_Bat750 I’m an 18-F and he’s an 18-M
2023.03.23 23:07 Then_Marionberry_259 MAR 23, 2023 LUN.TO LUNDIN MINING ANNOUNCES APPOINTMENT OF MARIA OLIVIA RECART TO BOARD OF DIRECTORS
![]() | https://preview.redd.it/eck2zm04bkpa1.png?width=3500&format=png&auto=webp&s=8e6c32bb72224bc2639010dffb72b2d56ce42f82 submitted by Then_Marionberry_259 to Treaty_Creek [link] [comments] https://preview.redd.it/nopifx34bkpa1.jpg?width=400&format=pjpg&auto=webp&s=40cc0b7783a224337d86c13ed57ded3f0c20b81f TORONTO , March 23, 2023 /CNW/ - (TSX: LUN) (Nasdaq Stockholm: LUMI) Lundin Mining Corporation ("Lundin Mining" or the "Company") is pleased to announce the appointment of Maria Olivia Recart to the Company's Board of Directors (the "Board") effective today. "We are excited to welcome Maria Olivia Recart to the Lundin Mining team and Board," commented Adam Lundin , Chair of Lundin Mining's Board of Directors. Peter Rockandel , CEO, added, " Maria Olivia's extensive knowledge, experience and recognized contributions in Chile make for an ideal addition to our Board. Her wealth of expertise rooted in experience on many environmental and social topics, including community engagement, government relations, sustainable supply chains and social values will provide invaluable perspective." Most recently, Maria Olivia was the Dean of Universidad Santo Tomás from 2019 to 2023, prior to which, she worked at BHP from 2010 to 2018 as Vice President ("VP") Corporate Affairs. As VP of Corporate Affairs for BHP, she was responsible for community engagement, communications, government relations and social value strategy for the Americas. During that time, she also served as a member of the Owners' Council of BHP's Escondida mine, where she advised on a range of operational, safety, financial, commercial, human resources and strategy issues. She was also appointed as VP of the board of directors of Fundación Chile , a mixed board composed of Chilean government officials and BHP appointed professionals; VP of Centro de Entrenamiento Industrial y Minero, an apprentice learning center to promote the skills needed in the workforce for productivity impact in mining and construction operations; and VP of Fundación Minera Escondida, a non-profit organization in the region of Antofagasta whose initiatives are focused on making an impact in the region's human and social capital and target minorities, the indigenous communities and women in particular. Maria Olivia also has experience in the public sector in Chile , where she served as Vice Minister of Finance between 2006 and 2010 and was responsible for the team that led Chile into the Organization for Economic Co-operation and Development. About Lundin Mining Lundin Mining is a diversified Canadian base metals mining company with projects and operations in Argentina , Brazil , Chile , Portugal , Sweden and the United States of America , primarily producing copper, zinc, gold and nickel. The information in this release is subject to the disclosure requirements of Lundin Mining under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below on March 23, 2023 at 16:30 Eastern Time Cautionary Statement on Forward-Looking Information Certain of the statements made and information contained herein is "forward-looking information" within the meaning of applicable Canadian securities laws. All statements other than statements of historical facts included in this document constitute forward-looking information, including but not limited to statements regarding the Company's plans, prospects and business strategies; the Company's guidance on the timing and amount of future production and its expectations regarding the results of operations; expected costs; permitting requirements and timelines; timing and possible outcome of pending litigation; the results of any Preliminary Economic Assessment, Feasibility Study, or Mineral Resource and Mineral Reserve estimations, life of mine estimates, and mine and mine closure plans; anticipated market prices of metals, currency exchange rates, and interest rates; the development and implementation of the Company's Responsible Mining Management System; the Company's ability to comply with contractual and permitting or other regulatory requirements; anticipated exploration and development activities at the Company's projects; the Company's integration of acquisitions and any anticipated benefits thereof; and expectations for other economic, business, and/or competitive factors. Words such as "believe", "expect", "anticipate", "contemplate", "target", "plan", "goal", "aim", "intend", "continue", "budget", "estimate", "may", "will", "can", "could", "should", "schedule" and similar expressions identify forward-looking statements. Forward-looking information is necessarily based upon various estimates and assumptions including, without limitation, the expectations and beliefs of management, including that the Company can access financing, appropriate equipment and sufficient labour; assumed and future price of copper, nickel, zinc, gold and other metals; anticipated costs; ability to achieve goals; the prompt and effective integration of acquisitions; that the political environment in which the Company operates will continue to support the development and operation of mining projects; and assumptions related to the factors set forth below. While these factors and assumptions are considered reasonable by Lundin Mining as at the date of this document in light of management's experience and perception of current conditions and expected developments, these statements are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: global financial conditions, market volatility and inflation, including pricing and availability of key supplies and services; risks inherent in mining including but not limited to risks to the environment, industrial accidents, catastrophic equipment failures, unusual or unexpected geological formations or unstable ground conditions, and natural phenomena such as earthquakes, flooding or unusually severe weather; uninsurable risks; project financing risks, liquidity risks and limited financial resources; volatility and fluctuations in metal and commodity demand and prices; delays or the inability to obtain, retain or comply with permits; significant reliance on a single asset; reputation risks related to negative publicity with respect to the Company or the mining industry in general; health and safety risks; risks relating to the development of the Josemaria Project; inability to attract and retain highly skilled employees; risks associated with climate change; compliance with environmental, health and safety laws and regulations; unavailable or inaccessible infrastructure, infrastructure failures, and risks related to ageing infrastructure; risks inherent in and/or associated with operating in foreign countries and emerging markets, including with respect to foreign exchange and capital controls; economic, political and social instability and mining regime changes in the Company's operating jurisdictions, including but not limited to those related to permitting and approvals, environmental and tailings management, labour, trade relations, and transportation; risks relating to indebtedness; the inability to effectively compete in the industry; risks associated with acquisitions and related integration efforts, including the ability to achieve anticipated benefits, unanticipated difficulties or expenditures relating to integration and diversion of management time on integration; changing taxation regimes; risks related to mine closure activities, reclamation obligations, environmental liabilities and closed and historical sites; reliance on key personnel and reporting and oversight systems, as well as third parties and consultants in foreign jurisdictions; information technology and cybersecurity risks; risks associated with the estimation of Mineral Resources and Mineral Reserves and the geology, grade and continuity of mineral deposits including but not limited to models relating thereto; actual ore mined and/or metal recoveries varying from Mineral Resource and Mineral Reserve estimates, estimates of grade, tonnage, dilution, mine plans and metallurgical and other characteristics; ore processing efficiency; community and stakeholder opposition; financial projections, including estimates of future expenditures and cash costs, and estimates of future production may not be reliable; enforcing legal rights in foreign jurisdictions; environmental and regulatory risks associated with the structural stability of waste rock dumps or tailings storage facilities; activist shareholders and proxy solicitation matters; risks relating to dilution; regulatory investigations, enforcement, sanctions and/or related or other litigation; risks relating to payment of dividends; counterparty and customer concentration risks; the estimation of asset carrying values; risks associated with the use of derivatives; relationships with employees and contractors, and the potential for and effects of labour disputes or other unanticipated difficulties with or shortages of labour or interruptions in production; conflicts of interest; existence of a significant shareholder; exchange rate fluctuations; challenges or defects in title; internal controls; compliance with foreign laws; potential for the allegation of fraud and corruption involving the Company, its customers, suppliers or employees, or the allegation of improper or discriminatory employment practices, or human rights violations; the threat associated with outbreaks of viruses and infectious diseases; risks relating to minor elements contained in concentrate products; and other risks and uncertainties, including but not limited to those described in the "Risk and Uncertainties" section of the Company's Annual Information Form and the "Managing Risks" section of the Company's MD&A for the year ended December 31, 2022 , which are available on SEDAR at [www.sedar.com*](http://www.sedar.com) under the Company's profile. All of the forward-looking statements made in this document are qualified by these cautionary statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, forecast or intended and readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions which may have been used. Should one or more of these risks and uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking information. Accordingly, there can be no assurance that forward-looking information will prove to be accurate and forward-looking information is not a guarantee of future performance. Readers are advised not to place undue reliance on forward-looking information. The forward-looking information contained herein speaks only as of the date of this document. The Company disclaims any intention or obligation to update or revise forward–looking information or to explain any material difference between such and subsequent actual events, except as required by applicable law.* Lundin Mining Announces Appointment of Maria Olivia Recart to Board of Directors (CNW Group/Lundin Mining Corporation) SOURCE Lundin Mining Corporation View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/23/c8646.html https://preview.redd.it/jqoq5z44bkpa1.png?width=4000&format=png&auto=webp&s=fc7004f59de4212ac10fd85010c192f1463f4bc7
|
2023.03.23 22:27 Plantmom1313 How to deal w a toxic friend
2023.03.23 18:07 StocksonHighAlertz NASDAQ $LSDI Licensed Manufacturer & Supplier of Psychedelics
![]() | Hello everyone and welcome to all our new members, submitted by StocksonHighAlertz to StocksMarket [link] [comments] As mentioned yesterday, you're joining us at a great time. Here's why... We have a recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance)Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. We will have an updated report on (LSDI) soon, The Team https://mailchi.mp/broadstreetalerts/lsdi-licensed-manufacturer-supplier-of-psychedelics?e=[UNIQID] |
2023.03.23 16:17 StocksonHighAlertz NASDAQ $LSDI Licensed Manufacturer & Supplier of Psychedelics
![]() | Hello everyone and welcome to all our new members, submitted by StocksonHighAlertz to smallstreetbets [link] [comments] As mentioned yesterday, you're joining us at a great time. Here's why... We have a recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance)Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. We will have an updated report on (LSDI) soon, The Team https://mailchi.mp/broadstreetalerts/lsdi-licensed-manufacturer-supplier-of-psychedelics?e=[UNIQID] |
2023.03.23 15:43 StocksonHighAlertz NASDAQ $LSDI Licensed Manufacturer & Supplier of Psychedelics
2023.03.23 15:00 StocksonHighAlertz NASDAQ $LSDI Licensed Manufacturer & Supplier of Psychedelics
2023.03.23 14:48 StocksonHighAlertz NASDAQ $LSDI Licensed Manufacturer & Supplier of Psychedelics
![]() | Hello everyone and welcome to all our new members, submitted by StocksonHighAlertz to 10xPennyStocks [link] [comments] As mentioned yesterday, you're joining us at a great time. Here's why... We have a recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance) Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/pyuik493uhpa1.png?width=700&format=png&auto=webp&s=5ca4b2dd443d79b43e35983787a245ac12513813 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. We will have an updated report on (LSDI) soon, The Team https://mailchi.mp/broadstreetalerts/lsdi-licensed-manufacturer-supplier-of-psychedelics?e=[UNIQID] |
2023.03.23 14:39 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready
2023.03.23 14:38 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to Wallstreetbetsnew [link] [comments] Great Partnership News with High Times Out Yesterday! Lucy Scientific Discovery Announces Partnership with High Times® to Develop and Distribute a New Line of Psychoactive Products ‘Mindful by Lucy’ New Line of Psychoactive Products VANCOUVER, British Columbia, March 23, 2023 (GLOBE NEWSWIRE) -- Lucy Scientific Discovery Inc. (“Lucy” or “The Company”) [NASDAQ:LSDI], a leading NASDAQ-listed psychedelic drug manufacturer, announced today the launch of a new line of unscheduled psychoactive compounds that will be available for sale throughout the United States, and where permitted throughout the rest of the world. The first line in the new family of brands contains Amanita Muscaria mushrooms, a psychoactive adaptogen. The product leverages the compounds of these mushrooms, and a proprietary blend of other natural functional ingredients, to create a transformative experience for consumers worldwide. This product line is named ‘Mindful by Lucy’. Lucy Scientific will produce Mindful with High Times, through a strategic partnership with Hightimes Holding Corp., the parent company of High Times®, the most well-known brand in cannabis. This collaboration aims to distribute and market the products initially through High Times' websites and social channels which reach over 10 million people across their owned and operated properties and social media accounts. With a product launch targeted for Q2 2023, this new line is well-positioned to capitalize on the growing market for psychoactive alternatives, which Forbes predicts will double to over $5 billion in gross sales by 2025. Lucy and High Times entered into a strategic investment agreement in January whereby Lucy received $2.5 million in advertising credits that will help launch the new brand into market through High Times channels and experiential events. Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., stated, “As awareness and acceptance of alternative treatments for various conditions, such as PTSD, anxiety disorders, and depression, continue to grow, adaptogens are emerging as a leading therapeutic remedy. This partnership between Lucy and High Times will enable the two companies to expand the reach of Lucy’s products and promote the potential health benefits to a broader audience.” FULL ARTICLE Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance)Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering”In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/b678w2prrhpa1.png?width=700&format=png&auto=webp&s=647a3588a84742645e1952faa2edf4e7f636c5b0 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.23 14:33 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to biotech_stocks [link] [comments] Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance) Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/gmq4z4ggrhpa1.png?width=700&format=png&auto=webp&s=6ec04d14294d7bd9c2f6bc0f3bd980527f55258a A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.23 14:20 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to SmallCapGrowth [link] [comments] Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance) Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/umk5rkd3phpa1.png?width=700&format=png&auto=webp&s=0b8d4d15013ee3e037d998fd9fa4bdf79f282781 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.23 14:19 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to BreakoutStocks [link] [comments] Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance) Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/jntsu3jyohpa1.png?width=700&format=png&auto=webp&s=1818a2acff8444f46eeee543a5f1c776899cc7c3 A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.23 14:18 SituationLive4406 $LSDI The first psychedelics manufacturing company to be listed on NASDAQ! Low float, building momentum, Recent IPO, Oversold, Looks Ready to Run
![]() | Hello everyone, submitted by SituationLive4406 to BroadStreetBets [link] [comments] Recent IPO report on the first psychedelics manufacturing company to be listed on NASDAQ! Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Hot sector, building momentum, low float, great setup Current price $1.39/share as of market close 03/22/23 Public Float 10.15M Shares (Source: Yahoo Finance) Range Since Inception $1.12 - $4.00/share About Lucy Lucy Scientific Discovery Inc. is a Nasdaq-listed (NASDAQ: LSDI) licensed producer of compounds for medicinal products. As granted by Health Canada’s Office of Controlled Substances, Lucy maintains a Controlled Drugs and Substances Dealer’s License, under Part J of the Food and Drug Regulations promulgated under the Food and Drugs Act (Canada), or a Dealer’s License. A Dealer’s License authorizes LSDI to develop, sell, deliver, and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors. Here is What Lucy Offers (Source: https://www.lucyscientific.com/) API and Target Formulation Production By leveraging various scalable production methods, Lucy is uniquely positioned to effectively support current and future market needs at competitive prices. Lucy's use of efficient and strategic manufacturing practices ensure a consistent and stable supply of the highest quality products from lab- to consumer-scale. Research, Development and Commercialization Support We will work directly with researchers and finished product manufacturers in a controlled and collaborative environment to facilitate healthy market growth. Our team aims to maximize your probability of success while minimizing the time and costs required to achieve your goals. Lucy (LSDI) has announced multiple breaking developments since its IPO last month. LSDI is “focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry”. The company’s mission is to make their “products and research services available for the development of medicines and experimental therapies to address certain psychiatric health disorders and other medical needs including various mental health and addiction disorders”. As the company stated in a recent press release: “The shift toward a public health response to the drug crisis will provide greater opportunities for people who use substances to connect with a growing range of harm reduction and treatment options.” In addition, as the company explained: “We look forward to a time when Lucy can safely supply harm reduction programs globally, aiming to reduce lethal and or negative consequences associated with adulterated drug supply, particularly considering that fentanyl overdose is the leading cause of deaths among 18 to 45-year-olds in the United States,” said Chris McElvany, the Company’s CEO. LSDI is “a licensed manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies”. Furthermore, “The Company has licenses to manufacture several controlled substances, including Psilocybin; MDMA; LSD; Psilocin; N,N-DMT; Mescaline; and 2C-B”. The company’s team “is composed of leading experts from pharmaceutical development, biotechnology, agriculture, applied chemistry, and consumer product manufacturing industries.” In addition, the company’s “executive team brings deep experience in the development and commercialization of products featuring controlled substances as well as the navigation of regulatory structures applicable to these products”. LSDI’s target customers “include an increasing number of the leading universities, hospitals and other public, private, and government institutions throughout the world that have launched research programs to conduct clinical studies aimed at understanding the therapeutic potential of a range of psychedelic substances”. Recently, the company achieved multiple milestones. On February 13, the company announced: “Lucy Scientific Discovery Announces Closing of its $7.5 Million Initial Public Offering” In addition, the company announced: “Lucy Scientific Discovery to Ring Nasdaq Closing Bell Today in Celebration of its IPO” Here are the company’s comments from this press release: “We are excited to celebrate this victory at Nasdaq's iconic bell ringing ceremony, as today marks an important milestone for the Company,” said Chris McElvany, the Company’s CEO. “We are pleased to celebrate many months of hard work and team effort that led to the successful completion of our IPO. Seeing Lucy, a pioneer in psychedelics manufacturing, take the next step in its development by becoming the first psychedelics manufacturing company to be listed on NASDAQ is a huge accomplishment. This milestone marks a significant step in the company's growth and plans for expansion. We look forward to the opportunities ahead of us to continue working on improving mental health and finding sustainable solutions for treatment.” Afterwards, the company announced another big accomplishment: “Lucy Scientific Discovery Announces First Commercial Sale of Psilocybin Following Initial Delivery of DMT and 5-MeO-DMT to Hadassah BrainLabs” Here are the company’s comments from this press release: “This first commercial sale of psilocybin marks a key operational milestone for the company as we shift from pre revenue to revenue producing, and are excited about further opportunities ahead,” said Lucy’s CEO Chris McElvany. “This transaction establishes Lucy’s ability to supply the global psychedelic community with compounds and services. Not only will it strengthen our relationship with the researchers at Hadassah-Hebrew University Medical Center, whose research helps lay the academic foundations indicating the potential of psychedelics, it will lead to the improvement of lives of millions of people around the world.” Most recently, on Friday, the company announced another significant development: “Lucy Scientific Teams Up with Pramantha Group to Secure Key Government Contracts and Grants to Enhance its Manufacturing Capabilities” As the company further explains: LSDI “partnered with Pramantha Group, a firm specializing in securing key government contracts and grants, to enhance its drug manufacturing capabilities and meet the growing demand for essential drugs and medical supplies”. Furthermore: “By leveraging Pramantha Group's expertise in identifying and capturing strategic funding and contract opportunities, Lucy Scientific is well-positioned to compete for and secure key government contracts and grants. With access to these funds, Lucy Scientific will be able to expand its drug manufacturing capabilities and contribute to the country's healthcare needs.” Here are some of the company’s comments from this press release: "Our partnership with Pramantha Group will help us navigate the complex landscape of government contracts and grants and identify the right opportunities to support our growth and contribute to the country's healthcare needs," said Lucy Scientific Discovery’s CEO Chris McElvany. "We are excited to work with Pramantha Group to enhance our drug manufacturing capabilities and play a key role in securing the domestic drug supply. Pramantha has a proven track record and a commitment to excellence that makes it an ideal partner for Lucy as we look to grow our operations." LSDI has multiple potential catalysts favoring a future of increased growth. The chart appears to be in bounce mode and is flashing oversold with an RSI of 35.34 https://preview.redd.it/95xu8ndmohpa1.png?width=700&format=png&auto=webp&s=2d6132901007974b02482221cc16248bea43aeeb A recent report from Data Bridge Market Research said that the psychedelic drugs market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 16.3% in the forecast period of 2020 to 2027 and expected to reach USD $6,859.95 million by 2027 from USD 2,077.90 million in 2019. Growing acceptance of psychedelic drugs for treating depression and increasing prevalence of depression and mental disorders are the factors for the market growth. Another report from Research And Markets upped the projection saying that the Psychedelic Drugs Market size is projected to reach USD $10.75 Billion by 2027, from USD 4.75 Bn in 2020 growing at a CAGR of 12.36% during 2021-2027. It is important to note that approximately 70% of the psychedelics market is attributable to psychedelics manufacturers. To help with your due diligence, here is a comprehensive report on the psychedelics market from Morgan Stanley. Disclaimer |
2023.03.23 13:39 simple-cranberry- It Keeps Getting Worse
2023.03.23 10:55 learnexams2023 When assignments start getting tough, take a break and learnexams will find study materials for you